Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623259 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
A Phase 1 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00623259 is a Phase 1 study that has completed, run by Bavarian Nordic. The registered enrollment target is 15 participants.
The verdict
NCT00623259, a Phase 1 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV multiantigen vaccine MVA-mBN120B in HIV-infected subjects. 15 subjects will receive immunizations at day 0, after 4 and 12 weeks at a dose of 2E8 TCID50 MVA-mBN120B. The vaccine will be administered subcutaneously.
Interventions
- BIOLOGICAL MVA-mBN120B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623259
The ClinicalTrials.gov registry entry for NCT00623259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA-mBN120B is the first listed.
NCT00623259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623259 about?
NCT00623259 is a clinical study titled "Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects". Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV multiantigen vaccine MVA-mBN120B in HIV-infected subjects. 15 subjects will receive immunizations at day 0, after 4 and 12 weeks at a dose of 2E8 TCID50 MVA-mBN120B. The vaccine will be administered subcutaneously.
What is the current status of trial NCT00623259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00623259?
The interventions under investigation include: MVA-mBN120B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00623259?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.